Clinical Trials Browser

Phase 1/2 × Leukemia, Myeloid, Acute × glasdegib × Clear all

NCT03390296 2023-09-05

OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia

Phase 1/2 Completed

50 enrolled 13 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute